Latest News

Senhwa’s Pidnarulex to Combined With Pfizer’s Talazoparib in a Clinical Trial for the Treatment of Prostate Cancer

Sep

22

2021

Senhwa Announces First Patient Successfully Dosed in Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations

Sep

10

2021

Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed

Aug

31

2021

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

Aug

25

2021

Senhwa’s Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

Aug

17

2021

Senhwa Completes Enrollment of a Phase 2 Investigator Initiated Trial of Silmitasertib as Novel Oral Drug for COVID-19

Aug

16

2021

Senhwa Signs Agreement with Taiwan’s CDE for COVID-19 Program Guiding Development of Silmitasertib

Aug

11

2021

Senhwa Announces IND Submission to India's CDSCO of a Phase II Clinical Study for Silmitasertib as a Potential COVID-19 Treatment

Jun

23

2021